Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
87111 trials found · Page 97 of 4356
-
Hope for rare heart disease: new drug shows promise in major trial
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.
Phase: PHASE3 • Sponsor: Alnylam Pharmaceuticals • Aim: Disease control
Last updated Apr 24, 2026 16:17 UTC
-
Major cancer trial tests two promising drug combinations for Tough-to-Treat lymphoma
Disease control OngoingThis phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 20, 2026 16:19 UTC
-
Immunotherapy plus chemo shows promise for tough endometrial cancers
Disease control OngoingThis phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent)…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
New drug combo aims to control rare blood cancer without transplant
Disease control OngoingThis is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
Major trial tests Drug's power to halt worsening of debilitating MS
Disease control OngoingThis study will evaluate the efficacy and safety of ocrelizumab (Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study will consist of the following phases: screening, d…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Fetal stem cells offer hope for babies with brittle bones
Disease control OngoingAn exploratory, open label, multiple dose, multicentre phase I/II trial evaluating safety and efficacy of postnatal or prenatal and postnatal administration of allogeneic expanded fetal mesenchymal stem cells for the treatment of severe Osteogenesis Imperfecta compared with a com…
Phase: PHASE1, PHASE2 • Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Can tighter blood pressure control save hearts in diabetes? major trial aims to find out
Disease control OngoingHigh blood pressure (BP) is a major public health concern, especially in low and middle income countries. High BP is a highly prevalent condition, and it is usually associated with diabetes mellitus. Both high BP and diabetes are risk factors for major cardiovascular events inclu…
Phase: NA • Sponsor: Hospital Israelita Albert Einstein • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
Race against time: giving medicine to babies before SMA symptoms strike
Disease control OngoingA global study of oral risdiplam in pre-symptomatic participants with spinal muscular atrophy (SMA).
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC
-
New hope for kids battling leukemia that Won't stay away
Disease control TerminatedPrimary Objective: Evaluate the anti-leukemic activity of isatuximab in combination with standard chemotherapies in pediatric participants of ages 28 days to less than 18 years with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML) Secondary…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for advanced colon cancer: immunotherapy trial seeks better control
Disease control OngoingThe main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Micro…
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New pill combo aims to boost lymphoma cure rates
⭐️ CURE ⭐️ Recruiting nowBackground: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated Apr 26, 2026 19:38 UTC
-
Global brain cancer trial aims to outsmart glioblastoma
Disease control Recruiting nowGlioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.
Phase: PHASE2, PHASE3 • Sponsor: Global Coalition for Adaptive Research • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC
-
Gene therapy aims to fix fabry disease with one infusion
Disease control CompletedThis is the first in human treatment with ST-920, an adeno-associated virus (AAV2/6) vector encoding the complementary deoxyribonucleic acid (cDNA) for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Breakthrough trial tests shot to help kids and adults eat foods They're allergic to
Disease control CompletedThis study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut). While each participant may be allergi…
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
CRISPR-Engineered 'Universal' immune cells tested to fight aggressive blood cancers
Disease control TerminatedThis is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Custom-Made vaccine trial aims to stop deadly skin Cancer's comeback
Disease control OngoingThe purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Phase: PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Major trial tests Immune-Boosting drug to fight advanced uterine cancer
Disease control OngoingThis is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplat…
Phase: PHASE3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
Gene therapy patients monitored for years in rare disease study
Disease control CompletedThe primary objective of this study is to determine the long-term safety of DTX401 following a single intravenous (IV) dose in adults with GSDIa.
Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Targeted radiation and transplant tested as lifeline for tough blood cancers
Disease control Recruiting nowThis phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back (recurrent) or isn't …
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Experimental hormone shot aims to boost pancreas cell transplants
Disease control Recruiting nowThis clinical study will evaluate the safety and effectiveness of Gastrin treatment with islet transplantation to help patients with difficult to control type 1 diabetes make insulin again and improve blood sugar control. This study involves two investigational (experimental) pr…
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC